Document Detail

Bosentan for the treatment of adult pulmonary hypertension.
MedLine Citation:
PMID:  21174507     Owner:  NLM     Status:  MEDLINE    
Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the management of pulmonary arterial hypertension (PAH; WHO group 1 pulmonary hypertension). Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class and quality of life, as well as delaying time to clinical worsening in patients with PAH. This article reviews the role of endothelin-1 in the pathogenesis and progression of PAH, the diagnosis of PAH and the pharmacology of bosentan, and summarizes the current available evidence for the safety and efficacy of bosentan for the treatment of PAH as a monotherapy and combination therapy, as well as its role in the management of other forms of pulmonary hypertension.
Nathan Dwyer; David Kilpatrick
Related Documents :
21642077 - Successful right coronary artery drug-eluting stent implantation in a male patient with...
21497477 - Delayed postpartum hemorrhage resulting from uterine artery pseudoaneurysm rupture.
15614847 - Prenatal sonographic delineation of the complex cardiac anatomy of thoraco-omphalopagus...
10761587 - Accessory pulsatile organs: evolutionary innovations in insects.
3596157 - Primary aortoduodenal fistula--report of an autopsy case.
22437057 - Thoracic aortic stent grafting in patients with connective tissue disorders: a word of ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Future cardiology     Volume:  7     ISSN:  1744-8298     ISO Abbreviation:  Future Cardiol     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-22     Completed Date:  2011-04-26     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  101239345     Medline TA:  Future Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  19-37     Citation Subset:  IM    
Cardiology Department, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Disease Progression
Exercise Tolerance / drug effects
Hemodynamics / drug effects
Hypertension, Pulmonary / drug therapy*,  physiopathology,  psychology
Quality of Life
Receptors, Endothelin / antagonists & inhibitors*,  drug effects
Sulfonamides / therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Receptors, Endothelin; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Next Document:  Cardiomyocyte transverse tubule loss leads the way to heart failure.